Orthogon Therapeutics
Orthogon Therapeutics49About
What does Orthogon Therapeutics do?
Orthogon Therapeutics is a biotechnology startup focused on developing a first-in-class oral therapy to treat BK polyomavirus (BKV) infections. BKV infections are a significant cause of complications in transplant patients, and currently, there are no approved treatments. The company's pioneering therapy aims to address the full spectrum of BKV infection, from early reactivation to more severe manifestations.
What is Orthogon Therapeutics's revenue?
StartupHub estimates Orthogon Therapeutics's annual revenue at $451K (range $249K to $1.3M, 68% confidence), based on comparable companies in the sector.
What is Orthogon Therapeutics's valuation?
StartupHub estimates Orthogon Therapeutics's effective valuation at $137.7M (range $86.5M to $207.6M, 24% confidence), based on comparable companies in the sector.
How much funding has Orthogon Therapeutics raised?
Orthogon Therapeutics has raised a total of $35M in funding. The most recent round on record is Follow-on.
Where is Orthogon Therapeutics headquartered?
Orthogon Therapeutics is headquartered in Canton, Massachusetts, USA.
When was Orthogon Therapeutics founded?
Orthogon Therapeutics was founded in 2012.
What industry does Orthogon Therapeutics operate in?
Orthogon Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery, Clinical Trials.
How many employees does Orthogon Therapeutics have?
Orthogon Therapeutics has approximately 3 people on record.
What is Orthogon Therapeutics's current status?
Orthogon Therapeutics's current operating status is: Inactive.
No comments yet. Be the first to share your take.